Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000272470 | SCV000338049 | pathogenic | not provided | 2015-12-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001382219 | SCV001580890 | pathogenic | Qualitative or quantitative defects of dysferlin | 2024-06-24 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln1410*) in the DYSF gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DYSF are known to be pathogenic (PMID: 17698709, 20301480). This variant is present in population databases (rs769721856, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with DYSF-related conditions. ClinVar contains an entry for this variant (Variation ID: 285153). For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000272470 | SCV002021893 | pathogenic | not provided | 2020-07-27 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005025423 | SCV005659317 | pathogenic | Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset | 2024-02-12 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000984261 | SCV001132386 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2B | 2017-03-08 | no assertion criteria provided | clinical testing |